These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 1900059)

  • 1. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A.
    Corthier G; Muller MC; Wilkins TD; Lyerly D; L'Haridon R
    Infect Immun; 1991 Mar; 59(3):1192-5. PubMed ID: 1900059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.
    Permpoonpattana P; Hong HA; Phetcharaburanin J; Huang JM; Cook J; Fairweather NF; Cutting SM
    Infect Immun; 2011 Jun; 79(6):2295-302. PubMed ID: 21482682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.
    Babcock GJ; Broering TJ; Hernandez HJ; Mandell RB; Donahue K; Boatright N; Stack AM; Lowy I; Graziano R; Molrine D; Ambrosino DM; Thomas WD
    Infect Immun; 2006 Nov; 74(11):6339-47. PubMed ID: 16966409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interrelationships between digestive proteolytic activities and production and quantitation of toxins in pseudomembranous colitis induced by Clostridium difficile in gnotobiotic mice.
    Corthier G; Muller MC; Elmer GW; Lucas F; Dubos-Ramaré F
    Infect Immun; 1989 Dec; 57(12):3922-7. PubMed ID: 2680988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.
    Koon HW; Shih DQ; Hing TC; Yoo JH; Ho S; Chen X; Kelly CP; Targan SR; Pothoulakis C
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3214-23. PubMed ID: 23629713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.
    Roberts A; McGlashan J; Al-Abdulla I; Ling R; Denton H; Green S; Coxon R; Landon J; Shone C
    Infect Immun; 2012 Feb; 80(2):875-82. PubMed ID: 22144483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
    Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
    J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The roles of toxin A and toxin B in Clostridium difficile infection: insights from the gnotobiotic piglet model.
    Steele J; Parry N; Tzipori S
    Gut Microbes; 2014; 5(1):53-7. PubMed ID: 24394234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.
    Wang H; Sun X; Zhang Y; Li S; Chen K; Shi L; Nie W; Kumar R; Tzipori S; Wang J; Savidge T; Feng H
    Infect Immun; 2012 Aug; 80(8):2678-88. PubMed ID: 22615245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.
    Steele J; Mukherjee J; Parry N; Tzipori S
    J Infect Dis; 2013 Jan; 207(2):323-30. PubMed ID: 23125448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
    Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
    Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).
    Leav BA; Blair B; Leney M; Knauber M; Reilly C; Lowy I; Gerding DN; Kelly CP; Katchar K; Baxter R; Ambrosino D; Molrine D
    Vaccine; 2010 Jan; 28(4):965-9. PubMed ID: 19941990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain.
    Ryan ET; Butterton JR; Smith RN; Carroll PA; Crean TI; Calderwood SB
    Infect Immun; 1997 Jul; 65(7):2941-9. PubMed ID: 9199470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate.
    Lyerly DM; Bostwick EF; Binion SB; Wilkins TD
    Infect Immun; 1991 Jun; 59(6):2215-8. PubMed ID: 2037383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.
    Yang Z; Schmidt D; Liu W; Li S; Shi L; Sheng J; Chen K; Yu H; Tremblay JM; Chen X; Piepenbrink KH; Sundberg EJ; Kelly CP; Bai G; Shoemaker CB; Feng H
    J Infect Dis; 2014 Sep; 210(6):964-72. PubMed ID: 24683195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunisation of mares with binding domains of toxins A and B of Clostridium difficile elicits serum and colostral antibodies that block toxin binding.
    Artiushin S; Timoney JF; Fettinger M; Fallon L; Rathgeber R
    Equine Vet J; 2013 Jul; 45(4):476-80. PubMed ID: 23206274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equine hyperimmune serum protects mice against Clostridium difficile spore challenge.
    Yan W; Shin KS; Wang SJ; Xiang H; Divers T; McDonough S; Bowman J; Rowlands A; Akey B; Mohamed H; Chang YF
    J Vet Sci; 2014; 15(2):249-58. PubMed ID: 24136208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.
    Hussack G; Tanha J
    Toxins (Basel); 2010 May; 2(5):998-1018. PubMed ID: 22069622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.
    Torres JF; Lyerly DM; Hill JE; Monath TP
    Infect Immun; 1995 Dec; 63(12):4619-27. PubMed ID: 7591115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.